Affimed (NASDAQ:AFMD – Get Rating) was the recipient of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 3,140,000 shares, a decrease of 7.9% from the January 15th total of 3,410,000 shares. Based on an average daily trading volume, of 2,040,000 shares, the days-to-cover ratio is currently 1.5 days.
Analyst Upgrades and Downgrades
AFMD has been the subject of several analyst reports. SVB Leerink decreased their target price on Affimed from $10.00 to $6.00 and set an “outperform” rating for the company in a research report on Monday, December 12th. StockNews.com upgraded Affimed from a “sell” rating to a “hold” rating in a report on Monday, November 21st. Truist Financial lowered their price target on Affimed from $12.00 to $8.00 in a report on Monday, December 12th. Piper Sandler decreased their price objective on Affimed from $7.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, December 12th. Finally, HC Wainwright started coverage on shares of Affimed in a report on Monday, December 12th. They set a “buy” rating and a $6.00 target price on the stock. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $6.71.
Hedge Funds Weigh In On Affimed
Several hedge funds have recently modified their holdings of the stock. Advisor Group Holdings Inc. boosted its position in Affimed by 258.3% during the first quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 6,464 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Affimed by 23.9% in the 1st quarter. JPMorgan Chase & Co. now owns 68,895 shares of the biopharmaceutical company’s stock valued at $301,000 after buying an additional 13,300 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Affimed by 1.9% in the first quarter. Bank of New York Mellon Corp now owns 302,737 shares of the biopharmaceutical company’s stock valued at $1,323,000 after buying an additional 5,513 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Affimed during the 1st quarter worth about $726,000. Finally, Vanguard Group Inc. raised its holdings in shares of Affimed by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 1,386,701 shares of the biopharmaceutical company’s stock valued at $6,060,000 after purchasing an additional 5,499 shares during the period. Institutional investors own 61.73% of the company’s stock.
Affimed Price Performance
Shares of AFMD opened at $1.00 on Friday. The company has a quick ratio of 5.63, a current ratio of 5.65 and a debt-to-equity ratio of 0.07. Affimed has a twelve month low of $0.99 and a twelve month high of $5.10. The stock has a market capitalization of $123.42 million, a P/E ratio of -1.59 and a beta of 2.35. The company has a 50 day moving average of $1.19 and a 200-day moving average of $1.90.
Affimed (NASDAQ:AFMD – Get Rating) last released its earnings results on Tuesday, November 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.08. Affimed had a negative net margin of 189.04% and a negative return on equity of 48.46%. The business had revenue of $15.01 million during the quarter, compared to the consensus estimate of $7.66 million. As a group, equities research analysts forecast that Affimed will post -0.61 EPS for the current fiscal year.
About Affimed
Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs.
See Also
Receive News & Ratings for Affimed Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Affimed and related companies with MarketBeat.com’s FREE daily email newsletter.